» Articles » PMID: 3513504

Controlled Double-blind Trial of the Clinical Effect of Nifedipine in the Treatment of Idiopathic Raynaud's Phenomenon

Overview
Journal Am Heart J
Date 1986 Apr 1
PMID 3513504
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Twenty-six patients with idiopathic Raynaud's phenomenon participated in a double-blind, crossover clinical trial comparing the clinical effect of nifedipine with that of placebo. Four patients discontinued the study because of side effects and one patient defaulted at the return visit. Nifedipine significantly reduced frequency and severity of attacks (p less than 0.01). In an overall evaluation of drug effectiveness, 19 of 21 patients preferred nifedipine to placebo (p less than 0.01). Nifedipine proved to be effective in the treatment of idiopathic Raynaud's phenomenon, but side effects should be expected in some 30%.

Citing Articles

Development of a UV-Stabilized Topical Formulation of Nifedipine for the Treatment of Raynaud Phenomenon and Chilblains.

Wasan E, Zhao J, Poteet J, Mohammed M, Syeda J, Soulsbury K Pharmaceutics. 2019; 11(11).

PMID: 31717566 PMC: 6920966. DOI: 10.3390/pharmaceutics11110594.


Calcium channel blockers for primary and secondary Raynaud's phenomenon.

Rirash F, Tingey P, Harding S, Maxwell L, Tanjong Ghogomu E, Wells G Cochrane Database Syst Rev. 2017; 12:CD000467.

PMID: 29237099 PMC: 6486273. DOI: 10.1002/14651858.CD000467.pub2.


Calcium channel blockers for primary Raynaud's phenomenon.

Ennis H, Hughes M, Anderson M, Wilkinson J, Herrick A Cochrane Database Syst Rev. 2016; 2:CD002069.

PMID: 26914257 PMC: 7065590. DOI: 10.1002/14651858.CD002069.pub5.


Raynaud's phenomenon (primary).

Pope J BMJ Clin Evid. 2013; 2013:1119.

PMID: 24112969 PMC: 3794700.


Raynaud's phenomenon (primary).

Pope J BMJ Clin Evid. 2011; 2011.

PMID: 21401971 PMC: 3275138.